These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23553575)

  • 41. Exposure to attention deficit hyperactivity disorder medications during pregnancy.
    Humphreys C; Garcia-Bournissen F; Ito S; Koren G
    Can Fam Physician; 2007 Jul; 53(7):1153-5. PubMed ID: 17872810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
    Shih HH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):9-19. PubMed ID: 30457349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G; Besag FM
    Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-Dependent Enuresis in Methylphenidate Use.
    Güleşen O; Bodur Ş; Cöngöloğlu A
    Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):184-186. PubMed ID: 36314572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
    Brown TE
    J Child Adolesc Psychopharmacol; 2004; 14(1):129-36. PubMed ID: 15142400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [What's new about hyperactivity disorder in children?].
    Le Heuzey MF
    Arch Pediatr; 2008 Jul; 15(7):1249-52. PubMed ID: 18485682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic effect of amphetaminil on enuresis nocturna primaria in children with hyperkinetic syndrome.
    Drtílková I; Misurec J; Balastíková B
    Homeost Health Dis; 1991; 33(5-6):288. PubMed ID: 18265500
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 54. [Autism and attention deficit hyperactivity disorder: pharmacological intervention].
    Fernández-Jaén A; Martín Fernández-Mayoralas D; Fernández-Perrone AL; Calleja-Pérez B; Muñoz-Jareño N; López-Arribas S
    Rev Neurol; 2013 Sep; 57 Suppl 1():S205-10. PubMed ID: 23897149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
    Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atomoxetine for the treatment of pediatric nocturnal enuresis.
    Shatkin JP
    J Child Adolesc Psychopharmacol; 2004; 14(3):443-7. PubMed ID: 15650501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.
    Robertson MM
    Eur Child Adolesc Psychiatry; 2006 Feb; 15(1):1-11. PubMed ID: 16514504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New treatments and approaches for attention deficit hyperactivity disorder.
    Newcorn JH
    Curr Psychiatry Rep; 2001 Apr; 3(2):87-91. PubMed ID: 11276402
    [No Abstract]   [Full Text] [Related]  

  • 59. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
    Wilens TE; Hammerness P; Utzinger L; Schillinger M; Georgiopoulous A; Doyle RL; Martelon M; Brodziak K
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):485-92. PubMed ID: 19877972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Shih HH; Pan YL; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):148-158. PubMed ID: 31794244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.